Armata Pharmaceuticals, Inc.
ARMP
$9.00
$0.182.04%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.90M | 5.05M | 6.87M | 4.70M | 5.17M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.90M | 5.05M | 6.87M | 4.70M | 5.17M |
| Cost of Revenue | 9.49M | 11.47M | 15.13M | 15.29M | 17.88M |
| Gross Profit | -4.59M | -6.42M | -8.26M | -10.59M | -12.70M |
| SG&A Expenses | 20.41M | 20.71M | 20.84M | 21.66M | 21.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.13M | 38.40M | 42.20M | 45.10M | 47.61M |
| Operating Income | -31.22M | -33.35M | -35.33M | -40.40M | -42.44M |
| Income Before Tax | -173.80M | -46.90M | -25.71M | -426.00K | -18.92M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -173.80 | -46.90 | -25.71 | -0.43 | -18.92 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -173.80M | -46.90M | -25.71M | -426.00K | -18.92M |
| EBIT | -31.22M | -33.35M | -35.33M | -40.40M | -42.44M |
| EBITDA | -29.69M | -31.86M | -33.89M | -39.02M | -41.11M |
| EPS Basic | -4.79 | -1.30 | -0.71 | -0.01 | -0.52 |
| Normalized Basic EPS | -0.82 | -0.83 | -0.84 | -0.90 | -0.91 |
| EPS Diluted | -4.81 | -1.91 | -1.32 | -1.12 | -1.62 |
| Normalized Diluted EPS | -0.74 | -0.66 | -0.66 | -0.64 | -0.72 |
| Average Basic Shares Outstanding | 144.96M | 144.79M | 144.74M | 144.70M | 144.64M |
| Average Diluted Shares Outstanding | 168.25M | 190.98M | 190.93M | 212.99M | 189.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |